Related Experiment Video
Updated: Jan 10, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month,
Claudia Bernárdez1, Sebastian Podlipnik2, Gillian E Westgate3
1Clínica AB Derma, Madrid, Spain.
Introduction:
Hair loss is a multifactorial and complex condition influenced by hormonal changes, nutritional deficiencies, genetic predisposition, oxidative stress, aging, inflammation, and psychological stress. This 6-month study evaluated the hair growth-promoting efficacy and safety of a drinkable nutraceutical (Olistic© Women) formulated with standardized ingredients to support hair health through multiple biological pathways.
Methods:
A total of 106 premenopausal female subjects (18-40 years) clinically diagnosed with telogen effluvium were randomized in a double-blind manner into the active (n = 53) or placebo (n = 53) arm, taking 1 vial (25 mL) per day for 6 months. The primary endpoint was the increase in hair density from baseline versus placebo assessed by phototrichoscopy using TrichoScan®; the secondary endpoints were the change in anagen-to-catagen/telogen (A:C/T) ratio assessed by phototrichogram using TrichoScan®, as well as safety and tolerability. This study was reviewed and approved (approval number 20230918-EC48.23) by the Comité de Ética de la Investigación con medicamentos (CEIm) Regional de la Comunidad de Madrid in Madrid, Spain.
Results:
Daily oral supplementation with the active product was well tolerated and resulted in a statistically significant increase in hair density versus placebo at day 90 (17.53 ± 2.46 vs 9.56 ± 2.43 hairs/cm2; P = 0.02) and day 180 (27.31 ± 2.61 vs 18.23 ± 2.98 hairs/cm2; P < 0.01). The A:C/T ratio showed a statistically significant increase from day 0 to day 180 in the active arm (from 8.20:1 to 14.19:1) versus placebo (from 7.43:1 to 8.76:1) (P < 0.001).
Conclusion:
The tested nutraceutical showed a statistically significant increase in hair density and A:C/T ratio compared to placebo over 6 months in premenopausal women with telogen effluvium. These results not only support efficacy and safety of the tested nutraceutical but also that a multifactorial nutraceutical approach can effectively manage telogen effluvium in premenopausal women.
Trial Registration:
ClinicalTrials.gov identifier, NCT07111312 (retrospectively registered 07/2025).
More Related Videos
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:28Menopause